

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:
NDA 20-702/S031

Trade Name: Lipitor Tablets

Generic Name: atorvastatin

Sponsor: Pfizer, Inc.

Approval Date: December 27, 2001

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:
NDA 20-702/S031

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Approvable Letter	
Labeling	
Medical Review(s)	
Chemistry Review(s)	X
Pharmacology Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Clinical Pharmacology/ Biopharmaceutics Review(s)	
Administrative/Correspondence Document(s)	X

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:
NDA 20-702/S031

APPROVAL LETTER



NDA 20-702/S-031

Pfizer Inc.
Attention: Rita A. Wittich
Vice President, Worldwide Regulatory Strategy
235 East 42nd Street
New York, NY 10017

Dear Ms. Wittich:

Please refer to your supplemental new drug application dated November 7, 2001, received November 8, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lipitor (atorvastatin calcium) tablets.

This "Changes Being Effected in 30 days" supplemental new drug application provides for the addition of Pfizer's Parsippany, New Jersey site, as a new packaging and analytical testing site for Lipitor (atorvastatin calcium) 10 mg tablets in foil/foil blisters.

We have completed the review of this supplemental application, and it is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Margaret Simoneau, R.Ph., Regulatory Project Manager, at (301) 827-6411.

Sincerely,

{See appended electronic signature page}

Stephen K. Moore, Ph.D.
Chemistry Team Leader I, DNDC II for the
Division of Metabolic and Endocrine Drug Products,
(HFD-510)
DNDC II, Office of New Drug Chemistry
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/


Stephen Moore
12/27/01 10:28:42 AM

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:
NDA 20-702/S031

CHEMISTRY REVIEW(S)

CHEMIST'S REVIEW

1. Organization CDE/HFD-510 Division Of Metabolism And Endocrine Drug Products		2. NDA # 20-702 Approved: 17-Dec-1996	
3. Name and Address of Applicant Pfizer Ireland Pharmaceuticals ¹ Pottery Road Dun Laoghaire County Dublin Ireland		4. Supplement SCM-031 Doc. 07-NOV-2001 Rec. 08-NOV-2001	
		5. Name of the Drug Lipitor Tablets	
		6. Nonproprietary Name Atorvastatin Calcium	
7. Supplement provides for the addition of the Pfizer's Parsippany, New Jersey site, as a new packaging and analytical testing site for Lipitor (atorvastatin calcium) 10-mg tablets in foil/foil blisters.		8. Amendment --	
9. Pharmacological Category Lipid Modifier. HMG-CoA reductase inhibitor/ Antihyperlipoproteinemic agent.		10. How Dispensed Rx	11. Related -N. A.-
12. Dosage Form Tablet		13. Potency 10-, 20-, 40- and 80-mg	
14. Chemical Name and Structure Atorvastatin Calcium (C ₃₃ H ₃₄ FN ₂ O ₅) ₂ Ca FW = 2 x 557.7 + 40.0 = 1155.38 (anhydrous calcium salt) CAS 134523-03-8 CAS 134523-00-5 (atorvastatin) FW free acid C ₃₃ H ₃₄ FN ₂ O ₅ = 558.66 FW calcium salt trihydrate (C ₃₃ H ₃₄ FN ₂ O ₅) ₂ Ca·3H ₂ O = 1209.42			
[R-(R*,R*)]-2-(4-fluorophenyl)-β, -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)			
15. Comments: This CBE-30 days supplement, SCM-030, adds the Pfizer's Parsippany, New Jersey site, as a new packaging and analytical testing laboratory for Lipitor (atorvastatin calcium) 10-mg tablets packaged in foil/foil blisters. Parke-Davis Pharmaceutical Ltd., a Division of Warner-Lambert Company, originally submitted NDA 20-702, approved on 17-DEC-1996. Parke-Davis Pharmaceuticals is now a subsidiary of Pfizer, Inc. In support of this supplement the applicant, Pfizer Pharmaceutical Group, provides a copy of a certification letter of Parsippany facility conformance with cGMP regulations 21 CFR §210 and 211, statement of stability commitment and stability protocol, and copies of the [approved] regulatory analytical methods for Lipitor tablets. This facility was found acceptable based on profile by the Office of Compliance (letter dated 27-NOV-2001 is attached). <i>The provided CMC information</i> is in accordance with the Agency guidance for industry "Changes to an approved NDA or ANDA" and "Post-approval changes-analytical testing laboratory site (PAC-ATLS)" and <i>meets the regulatory requirements</i> .			
16. Conclusions and Recommendations: The Pfizer's Parsippany, New Jersey site, is adequate for the packaging and analytical testing laboratory of Lipitor 10-mg tablets, in foil/foil blisters. Issue Approval Letter.			
17. Reviewer Name (and Signature)		Date Completed 27-NOV-2001	
Xavier Ysern, PhD			
R/D Initialed by Stephen Moore, PhD Chemist Team Leader		filename: /nda/20702s31.doc	

SS-CBE-30 AP

¹ Authorized USA Agent: Pfizer Inc., 235 East 42nd Street, 2800 Plymouth Road, New York, NY 10017 phone: (212) 733-4394

27-NOV-2001

FDA CDER EES
ESTABLISHMENT EVALUATION REQUEST
SUMMARY REPORT

Page 1 of 1

Application: NDA 20702/031	Priority: 1P	Org Code: 510
Stamp: 08-NOV-2001 Regulatory Due: 08-MAY-2002	Action Goal:	District Goal: 03-APR-2002
Applicant: PFIZER	Brand Name: LIPITOR	
235 EAST 42ND ST	Established Name:	
NEW YORK, NY 10017	Generic Name: ATORVASTATIN CALCIUM	
	Dosage Form: TAB (TABLET)	
	Strength: 10, 20, 40 AND 80 MG	
FDA Contacts: M. SIMONEAU (HFD-510)	301-827-6411	, Project Manager
X. YSERN (HFD-510)	301-827-6420	, Review Chemist
S. MOORE (HFD-510)	301-827-6430	, Team Leader

Overall Recommendation:

ACCEPTABLE on 27-NOV-2001 by J. D AMBROGIO (HFD-324) 301-827-0062

Establishment: 2211583	DMF No:
PFIZER INC	AADA No:
100 JEFFERSON RD	
PARSIPPANY, NJ 07054	

Profile: TCM	OAI Status: NONE	Responsibilities: FINISHED DOSAGE OTHER TESTER
Last Milestone: OC RECOMMENDATION		FINISHED DOSAGE PACKAGER
Milestone Date: 27-NOV-2001		
Decision: ACCEPTABLE		
Reason: BASED ON PROFILE		

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Xavier Ysern
11/28/01 09:29:16 AM
CHEMIST

AP

Stephen Moore
12/3/01 02:21:46 PM
CHEMIST

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:
NDA 20-702/S031

**ADMINISTRATIVE and CORRESPONDENCE
DOCUMENTS**



NDA 20-702/S-031

CBE-30 SUPPLEMENT

Pfizer Ireland Pharmaceuticals
Attention: Rita A. Wittich
Vice President, Worldwide Regulatory Strategy
235 East 42nd Street, 150/7/12
New York, NY 10017

Dear Ms. Wittich:

We have received your supplemental drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: Lipitor (atorvastatin calcium) Tablets

NDA Number: 20-702

Supplement Number: S-031

Date of Supplement: November 7, 2001

Date of Receipt: November 8, 2001

This supplemental application, submitted as a "Supplement - Changes Being Effected in 30 days" supplement, proposes to add Pfizer's Parsippany, NJ site as an additional packaging site and analytical testing laboratory for atorvastatin calcium 10 mg tablets.

Unless we notify you within 60 days of our receipt date that the application is not sufficiently complete to permit a substantive review, this application will be filed under section 505(b) of the Act on January 7, 2002, in accordance with 21 CFR 314.101(a). If the application is filed, the user fee goal date will be May 8, 2002.

Please cite the application number listed above at the top of the first page of any communications concerning this application. All communications concerning this supplemental application should be addressed as follows:

U.S. Postal Service/Courier/Overnight Mail:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Metabolic and Endocrine Drug Products, HFD-510
Attention: Division Document Room, 14B-19
5600 Fishers Lane
Rockville, Maryland 20857

If you have any questions, call me at (301) 827-6411.

Sincerely,

{See appended electronic signature page}

Margaret Simoneau, R.Ph.
Regulatory Project Manager
Division of Metabolic and Endocrine Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Margaret Simoneau
11/20/01 09:16:27 AM


Regulatory Affairs
Pfizer Inc
235 East 42nd Street 150/7/12
New York, NY 10017
212 733 4394 212 857 3558
Email chris.a.graham@pfizer.com

ORIGINAL



Pfizer Pharmaceuticals Group

Christopher A. Graham
Associate Director
Worldwide Regulatory Strategy



November 7, 2001

David Orloff, MD
Division of Metabolism and Endocrine
Drug Products (HFD-510)
Document Control Room 14B-45
Center for Drug Evaluation and Research
Food and Drug Administration
Parklawn Building
5600 Fishers Lane
Rockville, MD 20857

NDA NO. 20702 REF. NO. 031
NDA SUPPL FOR SCM

Re: NDA 20-702 Lipitor (Atorvastatin Calcium) Tablets Supplement-Changes Being Effected in 30 days.


Dear Dr. Orloff:

On behalf of, and as agent for Pfizer Ireland Pharmaceuticals, formerly known as Warner Lambert Export, Limited, reference is made to NDA 20-702 for Lipitor® (atorvastatin calcium) tablets. The NDA is being supplemented to add Pfizer's Parsippany, NJ site as an additional packaging site and analytical testing laboratory for atorvastatin calcium 10 -mg tablets.

In accordance with the FDA's Guidance for Industry- *Changes to an Approved NDA or ANDA and PAC-ATLS: Postapproval Changes-Analytical Testing Laboratory Site*, this supplement is being filed as an Operations and Analytical Testing Laboratory Site Change after 30- days from the date of this submission. Ongoing stability data for atorvastatin calcium 10-mg tablets packaged at the Pfizer Parsippany site will be submitted in subsequent annual reports.

Please do not hesitate to contact me at (212) 733-4394, if you have any questions or concerns regarding this matter.

Sincerely,


Christopher A. Graham